Free Trial
NASDAQ:HCWB

HCW Biologics 4/1/2024 Earnings Report

HCW Biologics logo
$7.03 -0.60 (-7.86%)
Closing price 05/5/2025 03:59 PM Eastern
Extended Trading
$7.04 +0.01 (+0.14%)
As of 04:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCW Biologics EPS Results

Actual EPS
-$12.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

HCW Biologics Revenue Results

Actual Revenue
$1.32 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HCW Biologics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

HCW Biologics' next earnings date is estimated for Wednesday, May 21, 2025, based on past reporting schedules.

Conference Call Resources

HCW Biologics Earnings Headlines

Hcw Biologics Inc trading halted, news pending
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
HCW Biologics files to sell 7.1M shares of common stock for holders
HCW Biologics approves 1-for-40 reverse stock split
See More HCW Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email.

About HCW Biologics

HCW Biologics (NASDAQ:HCWB), a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

View HCW Biologics Profile

More Earnings Resources from MarketBeat